<?xml version="1.0" encoding="UTF-8"?>
<ref id="emmm201910938-bib-0015">
 <mixed-citation publication-type="journal" id="emmm201910938-cit-0015">
  <string-name>
   <surname>Boutin</surname>
   <given-names>S</given-names>
  </string-name>, 
  <string-name>
   <surname>Monteilhet</surname>
   <given-names>V</given-names>
  </string-name>, 
  <string-name>
   <surname>Veron</surname>
   <given-names>P</given-names>
  </string-name>, 
  <string-name>
   <surname>Leborgne</surname>
   <given-names>C</given-names>
  </string-name>, 
  <string-name>
   <surname>Benveniste</surname>
   <given-names>O</given-names>
  </string-name>, 
  <string-name>
   <surname>Montus</surname>
   <given-names>MF</given-names>
  </string-name>, 
  <string-name>
   <surname>Masurier</surname>
   <given-names>C</given-names>
  </string-name> (
  <year>2010</year>) 
  <article-title>Prevalence of serum IgG and neutralizing factors against adeno‐associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors</article-title>. 
  <source xml:lang="en">Hum Gene Ther</source>
  <volume>21</volume>: 
  <fpage>704</fpage>–
  <lpage>712</lpage>
  <pub-id pub-id-type="pmid">20095819</pub-id>
 </mixed-citation>
</ref>
